This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. What is AtrialFibrillation?
(MedPage Today) -- LONDON -- For patients with atrialfibrillation (Afib) and stable coronaryarterydisease (CAD), edoxaban (Savaysa) monotherapy improved net outcomes weighing together bleeding and ischemic events as compared with dual antithrombotic.
In patients with high-risk atrialfibrillation (AFib) and stable coronaryarterydisease, endoxaban monotherapy when given as a long-term antithrombotic therapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, based on findings from the EPIC-CAD trial presented at ESC Congress 2024 in London and simultaneously (..)
Introduction:Anticoagulation (AC) is the mainstay of thromboprophylaxis for stroke prevention in atrialfibrillation (AF) and is recommended. PSM components were age, gender, race, PPI use, anti-platelets, hypertension, coronaryarterydisease, heart failure, COPD, and CKD.
Note: Due to the limited number of normally conducted beats — it is hard to be sure whether the underlying rhythm is sinus with baseline artefact or atrialfibrillation. A coronary angiogram was done that did not show significant coronaryarterydisease. There a two PVCs.
Case submitted and written by Mazen El-Baba MD, with edits from Jesse McLaren and edits/comments by Smith and Grauer A 90-year old with a past medical history of atrialfibrillation, type-2 diabetes, hypertension, dyslipidemia, presented with acute onset chest/epigastric pain, nausea, and vomiting. The patient was placed on telemetry.
Introduction:Atrial fibrillation (AFib) is a major risk factor for ischemic stroke (IS). Our outcome was differentially expressed levels of proteins in stroke patients with AFib compared to patients without AFib. years, 50% males) classified into 11 AFib and 49 no AFib (Figure 1).
With the addition of Shockwave, Johnson & Johnson will expand its MedTech cardiovascular portfolio into two of the highest-growth, innovation-oriented segments of cardiovascular intervention – coronaryarterydisease (CAD) and peripheral arterydisease (PAD).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content